Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03516708 · ClinicalTrials.gov registry record · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
A Phase 1 study of Rectal Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT03516708 is a Phase 1 study of Rectal Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 49 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03516708, a Phase 1 study of Rectal Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
Conditions Studied
Interventions
- DRUG Epacadostat
- RADIATION Short-course radiation therapy
- DRUG CAPOX chemotherapy
- DRUG FOLFOX chemotherapy
Study Locations (4)
California
- University of California Irvine - Chao Family Comprehensive Cancer Center - Orange
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Henry Ford Cancer Institute - Detroit
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2030-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03516708
The ClinicalTrials.gov registry entry for NCT03516708 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Epacadostat is the first listed.
NCT03516708 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT03516708 about?
NCT03516708 is a clinical study titled "Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer". The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
What is the current status of trial NCT03516708?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2020-01-06. Estimated completion is 2030-08-12.
What conditions does trial NCT03516708 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT03516708?
The interventions under investigation include: Epacadostat (DRUG), Short-course radiation therapy (RADIATION), CAPOX chemotherapy (DRUG), FOLFOX chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03516708?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03516708 being conducted?
This trial has 4 study locations across California, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
F-Tryptophan PET/CT in Human Cancers
RECRUITING · Phase 1
-
Ultra-fractionated Radiotherapy for Rectal Cancer
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
RECRUITING · Phase 1
-
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.